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Choline acetyltransferase (ChAT) synthesizes the neurotransmitter acetylcholine in
cholinergic neurons, and mutations of this enzyme are linked to the neuromuscular
disorder congenital myasthenic syndrome (CMS). One CMS-related mutation, V18M,
reduces ChAT enzyme activity and cellular protein levels, and is located within a
highly-conserved N-terminal proline-rich motif at residues 14PKLPVPP20. We showed
previously that disruption of this proline-rich motif by either proline-to-alanine
mutation (P17A/P19A) or mutation of residue Val18 (V18M) enhances ubiquitination
and degradation of these mutant ChAT proteins expressed in cholinergic SN56
cells by an unknown mechanism. In this study, using proximity-dependent biotin
identification (BioID), co-immunoprecipitation and in situ proximity-ligation assay (PLA),
we identified the heat shock proteins (HSPs) HSC/HSP70 and HSP90 as novel ChAT
protein-interactors. These molecular chaperones are well-known for promoting the
folding and stabilization of cellular proteins. Thus, we found that inhibition of HSPs
by treatment of cells with either the HSC/HSP70 inhibitors 2-phenylethynesulfonamide
(PES) or VER-155008, or the HSP90 inhibitor 17-AAG reduced cellular ChAT activity
and solubility, and enhanced the ubiquitination and proteasome-dependent loss of ChAT
protein. Importantly, the effects of HSP inhibition were greater for mutant ChAT proteins
(P17A/P19A-ChAT and CMS-related V18M- and A513T-ChAT) compared to wild-type
ChAT. HSPs can promote ubiquitination and degradation of terminally misfolded proteins
through cooperative interaction with the E3 ubiquitin ligase CHIP/Stub1, and while we
show that ChAT interacts with CHIP in situ, siRNA-mediated knock-down of CHIP
had no effect on either wild-type or mutant ChAT protein levels. However, inhibition
of the endoplasmic reticulum (ER)- and HSP-associated co-chaperone p97/VCP
prevented degradation of ubiquitinated ChAT. Together, these results identify novel
mechanisms for the functional regulation of wild-type and CMS-related mutant ChAT
by pro-stabilizing HSPs and the pro-degradative co-chaperone p97/VCP that may have
broader implications for ChAT function during cellular stress and disease.
Keywords: choline acetyltransferase, BioID, heat shock proteins, ubiquitination, CHIP/Stub1, proximity-ligation
assay, Cdc48/p97/VCP
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INTRODUCTION
Choline O-acetyltransferase (ChAT, EC2.3.1.6) catalyzes
synthesis of the neurotransmitter acetylcholine (ACh) using the
substrates acetyl-CoA and choline (Oda, 1999; Abreu-Villaca
et al., 2011). ChAT is a phenotypic marker of both central
and peripheral cholinergic neurons where ACh is essential for
behavioral, cognitive, autonomic and neuromuscular functions
(Abreu-Villaca et al., 2011; Picciotto et al., 2012). To date,
multiple ChAT transcripts have been identified that are formed
by alternative splicing and differential use of the non-coding
exons R, N, M, S, and H (Benjanin et al., 1994; Misawa et al.,
1997; Oda, 1999; Oda et al., 2004). All transcripts encode a
common 69-kDa ChAT enzyme that is localized predominantly
to the neuronal cytoplasm where it generates ACh (Rylett and
Schmidt, 1993; Misawa et al., 1997; Dobransky et al., 2001; Ohno
et al., 2001). Additionally, in humans and non-human primates
only, the M-transcript also encodes for an 82-kDa ChAT protein
due to the presence of a unique in-frame translation initiation
codon located 5′ to the common translation initiation site for
69-kDa ChAT (Oda et al., 1992; Chireux et al., 1995; Misawa
et al., 1997; Ohno et al., 2001). This primate-specific 82-kDa
ChAT protein contains a nuclear localization signal (NLS)
located within its extended N-terminus that directs it to the
nucleus of cholinergic neurons in human brain and spinal cord
(Resendes et al., 1999; Gill et al., 2003, 2007). Though our lab has
shown that nuclear 82-kDa ChAT can synthesize ACh (Resendes
et al., 1999; Gill et al., 2003) and alter gene expression (Albers
et al., 2014; Winick-Ng et al., 2016), the function/s of this ChAT
protein remain under investigation.
Alterations in the catalytic activity of 69-kDa ChAT are found
in a number of neurological disorders, including Alzheimer’s
disease (AD) (Pakaski and Kalman, 2008), amyotrophic lateral
sclerosis (Kato, 1989) and Huntington’s disease (Lange et al.,
1992). Importantly, mutations in ChAT protein have been
causally-linked to the development of congenital myasthenic
syndrome (CMS), a rare and inheritable neuromuscular disorder
in which synaptic mechanisms are compromised, resulting
in chronic hypotonia and acute apnea (Engel et al., 2012,
2015). While mutations in proteins localized both pre- and
postsynaptically at neuromuscular junctions are linked to CMS
(Engel et al., 2012, 2015), in vitro electrophysiological studies
Abbreviations: 17-AAG, 17-allylamino-17-demethoxygeldanamycin; Aβ, β-
amyloid; ACh, acetylcholine; AD, Alzheimer’s disease; BioID, proximity-
dependent biotin identification; ChAT, choline acetyltransferase; CHIP, C-
terminus of HSC70-interacting protein; CMS, congenital myasthenic syndrome;
CQ, chloroquine; CTab, anti-ChAT carboxyl-terminal peptide antibody; E6-
AP, E6-associated protein; Eer1, Eeyarestatin I; eNOS, endothelial nitric oxide
synthase; ER, endoplasmic reticulum; ERAD, endoplasmic-reticulum-associated
protein degradation; GRP-78, 78-kDa glucose-regulated protein; HIF-1α, hypoxia-
inducible factor 1-alpha; Hop, HSP70-HSP90 organizing protein; HSC70, heat
shock cognate 71 kDa protein; HSP, heat shock protein; IP, immunoprecipitation;
LC-ESI-MS/MS, liquid chromatography-electrospray ionization-tandem mass
spectrometry; MALDI-TOF-MS, matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry; NLS, nuclear localization signal; nNOS, neuronal
nitric oxide synthase; PD, pull-down; PES, 2-phenylethynesulfonamide; PLA,
proximity ligation assay; RIPA, radioimmune precipitation buffer; SDD-AGE,
semi-denaturing detergent agarose gel electrophoresis; SH3, Src-homology 3; VCP,
Valosin-containing protein.
of CMS patients revealed that ACh synthesis can be impaired
directly (Engel et al., 1977; Engel and Lambert, 1987; Mora et al.,
1987). Subsequently, over 40 CMS-related missense mutations
have been identified in human 69-kDa ChAT protein, some of
which have been partially characterized biochemically (Ohno
et al., 2001; Byring et al., 2002; Kraner et al., 2003; Maselli et al.,
2003; Schmidt et al., 2003; Barisic et al., 2005; Mallory et al., 2009;
Yeung et al., 2009; Shen et al., 2011; Arredondo et al., 2015).
Severe CMS symptoms are associated with mutations
involving the ChAT active-site that impair substrate-binding,
reduce mutant ChAT protein levels and result in reduced ACh
synthesis (Ohno et al., 2001; Shen et al., 2011; Arredondo
et al., 2015). Interestingly, a V18M mutation identified in four
unrelated patients with severe CMS is located distal to the ChAT
active-site, but also reduces both ChAT protein levels and acetyl-
CoA affinity and catalytic efficiency (Shen et al., 2011; Arredondo
et al., 2015). Residue Val18 does not participate directly in
acetyl-CoA binding, but is located within a highly-conserved,
surface-exposed N-terminal proline-rich motif with sequence
14PKLPVPP20 that shares homology with the core PxxP binding-
motif for SH3-binding domains (Kim et al., 2006; Kurochkina
and Guha, 2013). We showed recently that ChAT protein
stability is regulated by the ubiquitin-proteasome system and,
importantly, that mutation of this proline-rich motif, including
P17A/P19A and CMS-related V18M, as well as the CMS-related
mutant A513T enhances the ubiquitination and proteasome-
dependent degradation of ChAT protein (Morey et al., 2016). The
mechanisms responsible for the basal regulation of ChAT protein
stability and/or for the changes observed following mutation of
ChAT, in particular disruption of the N-terminal proline-rich
motif, have not been elucidated.
Disease-related mutations can often lead to protein
misfolding, dysfunction and enhanced degradation. Heat
shock proteins (HSP), including HSP40, heat shock cognate
71 kDa protein (HSC70) and HSP90, act together as molecular
chaperones to regulate the folding of non-native nascent
proteins and to prevent protein misfolding and aggregation
(McClellan and Frydman, 2001; Richter et al., 2010). Protein-
damaging stresses, such as oxidative stress, can promote
protein misfolding, dysfunction, and cell death (Kalmar and
Greensmith, 2009; Vabulas et al., 2010). In response, stress-
induced expression of HSP70 attenuates protein misfolding,
stimulates refolding of stress-damaged proteins and prevents
aggregation of misfolded proteins (Mosser et al., 1997). In
neurodegenerative diseases, such as AD and Huntington’s
disease, HSPs can have a cytoprotective role by chaperoning
disease-associated aggregation-prone proteins (Lackie et al.,
2017). If protein misfolding is irreversible, such as during
chronic or intense proteotoxic stress or in the case of mutant
proteins, terminally misfolded proteins can be targeted
for degradation by the HSP-associated co-chaperone C-
terminus of HSC70-interacting protein (CHIP) (Ballinger
et al., 1999; Connell et al., 2001; Zhang et al., 2015). CHIP
is a member of the U-box family of E3 ubiquitin ligases that
has neuroprotective properties by regulating the degradation
of aggregation-prone tau protein (Petrucelli et al., 2004), as
well as amyloid precursor protein (Kumar et al., 2007) and the
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β-amyloid (Aβ) promoting enzyme β-secretase-1 (Singh and
Pati, 2015).
The goal of this study was to elucidate mechanisms involved
in regulation of ChAT protein stability. By comparing wild-type
ChAT with mutant ChAT proteins that we found previously to
undergo enhanced ubiquitination (i.e., P17A/P19A-, V18M-, and
A513T-ChAT) (Morey et al., 2016), we identified HSC/HSP70
and HSP90 as novel ChAT protein-interactors and show
that pharmacological inhibition of these HSPs results in loss
of cellular ChAT activity and enhanced ubiquitination and
degradation of ChAT. ChAT interacts with the E3 ligase
CHIP, though siRNA knock-down of CHIP has no effect
on ChAT protein levels. Lastly, pharmacological inhibition
of the endoplasmic reticulum (ER)- and HSP-associated co-
chaperone p97/VCP prevents degradation of ubiquitinated
ChAT. Collectively, this study identifies and characterizes the role
of multiple molecular chaperones in ChAT protein stability that
could have broader implications for dysregulation of ChAT under
conditions of cellular stress or in human disease.
MATERIALS AND METHODS
Protein Expression Plasmids
Plasmids were constructed by ligating full-length cDNAs
encoding wild-type human 69-kDa ChAT (Dobransky
et al., 2003) or mutant ChAT (P17A/P19A-ChAT, V18M-
ChAT, or A513T-ChAT) (Morey et al., 2016) to pcDNA3.1+
vector (Invitrogen) for expression in mammalian cells. For
proximity-dependent biotin identification (BioID) experiments,
pcDNA3.1/MCS-BirA(R118G)-HA (BirA∗; Addgene #36047)
(Roux et al., 2012) served as a template for the ligation of
PCR-amplified wild-type and P17A/P19A-ChAT cDNA. For the
heterologous expression of CHIP, a plasmid was kindly provided
by Dr. Yosef Shaul (Weizmann Institute of Science) with
permission by Dr. Cam Patterson (UNC School of Medicine).
CHIP cDNA was PCR amplified with the addition of a C-
terminal FLAG-tag and ligated to pcDNA3.1+. All expression
plasmids were verified by full-length DNA sequencing prior to
use.
Cell Culture, Experimental Treatments, and
Cell Lysis
Cholinergic SN56 neural cells (gift from Dr. J.K. Blusztajn,
Boston University) (Blusztajn et al., 1992) or HEK293 cells
(ATCC) were grown as monolayers in DMEM supplemented
with 5–10% FBS (Invitrogen) and 1% Pen-Strep at 37◦C
with 5% CO2. Prior to experimental treatments, cells were
transiently transfected by Lipofectamine 3,000 (Invitrogen) at
∼50% confluence for 18–24 h at 37◦C with plasmids above. All
laboratory procedures were conducted with Biosafety Approval
BIO-RRI-0022.
The impact of inhibition of HSC/HSP70, HSP90 or p97/VCP
function on ChAT steady-state protein levels was determined
in SN56 cells expressing either wild-type or mutant ChAT
proteins treated with varying concentrations of the HSC/HSP70
inhibitor VER-155008 (5–50µM; Sigma), HSP90 inhibitor 17-
AAG (0.5–2µM; StressMarq Biosciences) or p97/VCP inhibitor
Eeyarestatin-I (5–10µM; Sigma) for 18–24 h at 37◦C. Cells were
collected and lysed on ice in RIPA buffer (50mM Tris-HCl; pH
8.0, 150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% SDS) supplemented with mammalian protease inhibitor
cocktail (Sigma), phosphatase inhibitor cocktail (10mM NaF,
1mM Na3VO4, 20mM Na2HPO4, 3mM β-glycerolphosphate,
5mM sodium pyrophosphate), 50µM MG132 (Enzo Life
Sciences), 10mM N-ethylmaleimide (NEM; Calbiochem) and
800 U/ml DNase I (Invitrogen). Lysates were centrifuged for
10min at 21,000 g at 4◦C, denatured in 1x reducing Laemmli
sample buffer (63mM Tris-HCl; pH 6.8, 10% glycerol, 2% SDS,
0.005% bromophenol blue, 2.5% 2-mercaptoethanol) at 95◦C
for 10min, then analyzed by immunoblotting with anti-ChAT
primary antibody.
The effects of either proteasome or lysosome inhibition on
ChAT steady-state protein levels during HSC/HSP70 and HSP90
inhibition were investigated in SN56 cells expressing wild-type
or mutant ChAT. Cells were treated either alone with 40µM
VER-155008 or 1µM 17-AAG at 37◦C for 24 h or co-treated for
18 h with either 5µM MG132 or 50µM chloroquine (Sigma).
To lyse cells and release aggregated proteins following HSP
inhibition, cells were boiled at 95◦C for 5min and sonicated in
1% SDS lysis buffer (50mM Tris-HCl; pH 8.0, 150mM NaCl,
1% SDS) supplemented with protease/phosphatase inhibitors,
50µMMG132 and 10mMNEM. Protein samples were prepared
for anti-ChAT immunoblotting as above. Proteasome inhibition
by MG132 treatment or lysosome inhibition by chloroquine
treatment was validated by immunoblotting for the accumulation
of either ubiquitinated cellular proteins or for a lysosome-
associated isoform of microtubule-associated protein 1A/1B-
light chain 3 (LC3B-II), respectively (Tanida et al., 2008).
Cellular ChAT Assay
To measure cellular ChAT activity following HSC/HSP70 or
HSP90 inhibition SN56 cells transiently expressing wild-type
ChAT were treated with 40µM VER-155008 or 1µM 17-AAG
at 37◦C for 24 h. Cells were collected and lysed on ice in buffer
containing 10mM Na2HPO4; pH 7.4, 0.87mM EDTA, 0.5%
Triton X-100, and 1.5mM eserine sulfate, supplemented with
protease/phosphatase inhibitors (above) and 50µM MG132.
Lysates were centrifuged for 10min at 21,000 g at 4◦C and cellular
ChAT activity was analyzed by modified radioenzymatic assay
(Fonnum, 1969; Pongrac and Rylett, 1998).
Immunoprecipitation (IP) to Assess
Ubiquitination of ChAT
SN56 cells transfected to express either wild-type or mutant
ChAT were treated at 37◦C with 40µM VER-155008 for 24 h,
1µM 17-AAG for either 8 or 24 h, or 10µM Eeyarestatin-I for
18 h to inhibit HSC/HSP70, HSP90 or p97/VCP respectively.
To block degradation of ubiquitinated ChAT during HSP
inhibition cells were co-treated with 20µMMG132 for 6 h prior
to being collected; MG132 was omitted during assessment of
ChAT ubiquitination following p97/VCP inhibition. Cells were
lysed on ice in RIPA buffer supplemented with 0.5% SDS,
protease/phosphatase inhibitors (above), 50µM MG132 and
10mM NEM. Lysates were sonicated, centrifuged for 15min
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at 21,000 g at 4◦C, then aliquots of cleared whole cell lysates
were incubated with 25 µg/mg cellular protein of anti-ChAT
primary antibody (CTab) (Dobransky et al., 2003) at 4◦C for 18 h.
Immune complexes were captured onto protein-G Dynabeads
(Invitrogen) for 1 h at 4◦C, washed with RIPA buffer with 0.5%
SDS, then eluted into 50 µl of 2x Laemmli sample buffer at 85◦C
for 15min. IP samples were analyzed by immunoblotting with
anti-ChAT and anti-ubiquitin primary antibodies. Total protein
samples were prepared for immunoblotting by denaturing
whole cell lysates in 1x Laemmli sample buffer at 95◦C for
10min.
Co-Immunoprecipitation (co-IP) of ChAT
with CHIP or HSPs
For co-IP of ChAT with endogenous HSPs, endogenous
CHIP or heterologous FLAG-tagged CHIP either HEK293 or
SN56 cells were transfected to express either wild-type or
mutant ChAT protein alone or co-expressed with FLAG-CHIP.
Cells were collected on ice and lysed in co-IP lysis buffer
(10mM HEPES; pH 7.4, 5mM MgCl2, 1mM EGTA, 50mM
NaCl, 5% glycerol, 0.5% Triton X-100) supplemented with
protease/phosphatase inhibitors, 50µM MG132 and 10mM
NEM. Lysates were centrifuged for 15min at 15,000 g at 4◦C,
then aliquots of cleared whole cell lysates containing either
2mg (FLAG-CHIP) or 4mg (endogenous proteins) of protein
were incubated with CTab primary antibody at 4◦C for 18 h
as above. Immune complexes were captured onto protein-G
Dynabeads for 1 h at 4◦C, washed in co-IP lysis buffer, then
eluted into 50 µl of 2x Laemmli sample buffer at 85◦C for
15min. Co-IP samples were analyzed by immunoblotting. Total
protein samples were prepared by denaturing whole cell lysates
in 1x Laemmli sample buffer at 95◦C for 10min prior to
immunoblotting.
SDS-PAGE and Immunoblotting Analysis
Denatured protein samples from whole cell lysates and
anti-ChAT IP/co-IPs were resolved on 7.5–15% SDS-PAGE
gels, then transferred to PVDF membranes (Bio-Rad). For
immunoblotting, membranes were blocked for 1 h at room
temperature in 5% non-fat milk powder in PBS containing
0.15% Triton X-100 (PBST), followed by incubation overnight
at 4◦C with primary antibody. Probed membranes were
washed with PBST, and primary antibodies were detected using
1:10,000 peroxidase-coupled secondary antibodies (Jackson
ImmunoResearch) and Clarity Western ECL Substrate (Bio-
Rad) on a ChemiDoc MP system (Bio-Rad). The following
primary antibodies were used: 1:1,000 ChAT (CTab) (Dobransky
et al., 2003), 1:10,000 β-actin (Sigma), 1:10,000 GAPDH
(Cell Signalling), 1:1,000 HSC70 (StressMarq), 1:2,000 HSP70
(Thermo), 1:2,000 HSP90 (StressMarq), 1:1,000 CHIP (Santa
Cruz), 1:1,000 ubiquitin (Santa Cruz), 1:1,000 FLAG-M2
(Sigma), and 1:1,000 LC3B-I/II (Thermo). For anti-CHIP
immunoblotting from anti-ChAT co-IP samples, 1:1,000
VeriBlot IP secondary antibody (Abcam) was used to reduce
IgG light chain interference from detecting endogenous 35-kDa
CHIP.
Triton X-100 Fractionation of Cells for
Soluble/Insoluble ChAT and SDD-AGE
ChAT protein solubility was assessed in ChAT-
expressing SN56 cells following treatment with 20µM
2-phenylethynesulfonamide (PES; Sigma) at 37◦C for 24 h.
Cells were collected and lysed on ice in 0.1% Triton X-100 lysis
buffer (50mM Tris-HCL; pH 8.0, 150mM NaCl, 0.1% Triton
X-100) supplemented with protease/phosphatase inhibitors,
50µM MG132 and 10mM NEM. Lysates were centrifuged
for 15min at 15,000 g at 4◦C and aliquots of Triton-soluble
supernatant were prepared for immunoblotting by denaturing in
1x Laemmli sample buffer at 95◦C for 10min. Triton-insoluble
proteins were prepared for immunoblotting by washing Triton-
insoluble pellets once with ice-cold PBS, then denaturing the
pellets in an equal volume of 2x Laemmli sample buffer with
5% 2-mercaptoethanol at 85◦C for 15min prior to separation
on SDS-PAGE gels. Additionally, Triton-insoluble proteins
were analyzed in parallel by semi-denaturing detergent agarose
gel electrophoresis (SDD-AGE) to determine if PES treatment
results in generation of SDS-resistant ChAT aggregates. Briefly,
Triton-insoluble samples resuspended in 2x Laemmli sample
buffer with 5% 2-mercaptoethanol were resolved on 1.8%
agarose gels containing 0.5% SDS in 1x TAE buffer (40mM
Tris; pH 7.6, 20mM acetic acid, 1mM EDTA) supplemented
with 0.1% SDS. Resolved proteins were transferred to PVDF
membranes by overnight capillary transfer in 1x TBS with
10% methanol, then immunoblotted for ChAT protein as
above.
Proximity-Dependent Biotin Identification
(BioID)
HEK293 cells expressing wild-type- or P17A/P19A-ChAT-BirA∗
fusion proteins were live-labeled with 50µM biotin at 37◦C
for 24 h to allow proximity-dependent biotinylation of cellular
proteins. Controls cells were transfected with either empty vector
or plasmids encoding untagged ChAT or BirA∗ (Roux et al.,
2012). Cells were collected on ice and lysed in supplemented
RIPA buffer (above), centrifuged for 10min at 21,000 g at
4◦C, then aliquots of cleared whole cell lysate containing 5mg
protein were incubated with 50 µl of MyOne Streptavidin C1
Dynabeads (Invitrogen) at 4◦C for 18 h. Streptavidin pull-down
(PD) samples were washed with RIPA buffer and biotinylated
proteins were eluted into 50 µl of 2x Laemmli sample buffer at
85◦C for 15min prior to immunoblotting with 1:20,000 Pierce
High Sensitivity Streptavidin-HRP (Thermo) in PBST with 5%
BSA. Total protein samples were prepared by denaturing whole
cell lysates in 1x Laemmli sample buffer at 95◦C for 10min prior
to immunoblotting. For large-scale BioID to identify novel ChAT
protein-interactors, HEK293 cells expressing either untagged
ChAT (control) or ChAT-BirA∗ fusion proteins were live labeled
with 50µM biotin then collected, lysed and centrifuged as
above. Aliquots of cleared whole cell lysate containing 25mg
protein were incubated with 250 µl of MyOne Streptavidin
C1 Dynabeads at 4◦C for 18 h. Streptavidin PD samples were
washed, eluted into 100 µl of 2x Laemmli sample buffer, and
run on 10% SDS-PAGE gels. To visualize biotinylated proteins,
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the SDS-PAGE gel was stained using Pierce Silver Stain for Mass
Spectrometry (Thermo).
Mass Spectrometry
Following large-scale BioID proteins of interest were excised
from silver-stained SDS-PAGE gels using an Ettan Spot Picker
(GE Healthcare Life Sciences). In-gel digestion was performed at
the London Regional Proteomics Center - Functional Proteomics
Facility (FPF; Western University) using a MassPREP automated
digester station (PerkinElmer) where gel pieces were first
de-stained [50mM Na2S2O3 and 15mM K3Fe(CN)6], followed
by protein reduction (10mM dithiothreitol), alkylation (55mM
iodoacetamide), and tryptic digestion. Digested peptides
were extracted in 1% formic acid with 2% acetonitrile,
lyophilized, then dissolved in a 10% acetonitrile containing
0.1% trifluoroacetic acid prior to mass spectrometry by either
matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF-MS) or by liquid chromatography-
electrospray ionization-tandem mass spectrometry
(LC-ESI-MS/MS).
For MALDI-TOF-MS, tryptic-digested peptides were mixed
1:1 (v/v) with a 5 mg/mL α-cyano-4–hydroxycinnamic acid
MALDI matrix that was prepared in 6mM NH4H2PO4, 50%
acetonitrile, and 0.1% trifluoroacetic acid, then submitted to the
London Regional Proteomics Center - FPF (Western University)
for analysis. Mass spectrum were obtained using a TOF/TOF
5800 System (Applied Biosystems, Sciex) equipped with a
349 nm OptiBeam On-Axis laser using a laser pulse-rate of
400Hz. Reflectron positive mode was used and was externally
calibrated at 50 ppm mass tolerance and internally at 10
ppm. Each mass spectrum was collected as a sum of 500
shots. Data acquisition and processing were completed using
a TOF/TOF Series Explorer and Data Explorer respectively
(Applied Biosystems, Sciex). The resulting data were analyzed
using the online Mascot Server (Matrix Science) against the
NCBI Human protein database with the following selected as
variable modifications; biotin (K), carbamidomethyl (C), NEM
(C), oxidation (M). Peptide tolerance was set at ± 50 ppm for
protein identification.
For LC-ESI-MS/MS, tryptic-digested peptides were submitted
for protein identification by the London Regional Proteomics
Center–Biological Mass Spectrometry Laboratory (BMSL;
Western University). Briefly, digested peptides were injected
into and analyzed using a LC-ESI-MS/MS system comprised of
a nanoAcquity UPLC (Waters) followed by an in-line QExactive
Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo)
using a top-12 double-play method. For LC, peptides were
trapped onto a reverse-phase Acquity Symmetry C18 column,
5µm, 180µm × 200mm (Waters), and eluted/separated
from a Acquity Peptide BEH C18 column, 1.7 um, 75 um ×
250mm (Waters), and using and a H2O-acetonitrile with 0.1%
formic acid solvent gradient. Resulting data were analyzed
using Peaks 7.5 software (Bioinformatics Solutions Inc.,)
against the NCBI Human protein database allowing for variable
carbamidomethylation or modification of cysteine residues with
NEM with filter criteria of FDR = 1% and UP = 1 (unique
protein) to show protein identification.
In Situ Proximity Ligation Assay (PLA)
To evaluate in situ ChAT protein-interactors, SN56 cells were
plated on 35mm glass-bottom confocal dishes and transfected
to express wild-type ChAT. Cells were washed with HBSS,
formalin-fixed (4% paraformaldehyde in HBSS) for 15min,
permeabilized with 0.1% Triton X-100, blocked for 1 h in HBSS
supplemented with 3% donkey serum, then finally incubated for
1 h with primary antibodies targeting ChAT (1:100; Chemicon,
goat primary) together with either endogenous HSC70 (1:100;
StressMarq, mouse primary), HSP90 (1:200; StressMarq, mouse
primary) or CHIP (1:200; Santa Cruz, rabbit primary); all
steps were performed at room temperature. Controls cells
were transfected with empty vector or were not incubated
with primary antibodies. To visualize in situ interactions, we
utilized DuoLink PLA technology (Sigma) by incubating cells
with Duolink oligonucleotide-linked secondary antibodies (anti-
goat PLUS with anti-mouse MINUS or anti-rabbit MINUS)
for 1 h at 37◦C. Cells were then washed and incubated with
1 U/µL DNA ligase followed by 10 U/µL DNA polymerase
according to manufacturer’s instructions. Finally, cells were
overlaid with Duolink In Situ Mounting Medium with DAPI
and images were acquired using a Leica True Confocal
Scanner (TCS) 8 SpectroPhotometer (SP8; Leica Microsystems
Inc.,) confocal laser microscope with a 63x-magnification oil-
immersion objective (NA= 1.4), and processed using ImageJ 1.50
b software (NIH).
Small-Interfering RNA (siRNA)
Knock-Down of CHIP
SN56 cells were incubated for a total of 72 h at 37◦C with 25 nM
of either scramble-control siRNA (Silencer Select #4390843;
Thermo) or anti-Stub1/CHIP siRNA (Silencer Select ID: s80537;
Thermo) following transfection with siLentFect Lipid Reagent
(Bio-Rad). As a control, cells were mock transfected with
siLentFect alone. After 24 h of CHIP knock-down, cells were
transfected with Lipofectamine 3,000 to transiently express either
wild-type or mutant ChAT for an additional 48 h at 37◦C. Cells
were collected and lysed on ice in RIPA buffer containing 0.5%
SDS, protease/phosphatase inhibitors, 50µMMG132 and 10mM
NEM. Lysates were centrifuged for 10min at 21,000 g at 4◦C,
denatured in 1x Laemmli sample buffer at 95◦C for 10min, then
analyzed by immunoblotting.
Data Analysis
For immunoblots from cell lysates, immunoreactive protein
levels were measured by densitometry using ImageLab 5.0
software (Bio-Rad), then normalized to either β-actin or GAPDH
protein levels in the same sample and graphed as mean ±
SEM from n independent replicate experiments. For analysis
of anti-ChAT co-IP immunoblots, individual immunoreactive
bands for each co-immunoprecipitated protein (i.e. wild-type
and mutant ChAT proteins, HSC/HSP70, HSP90 or FLAG-
CHIP) were measured by densitometry then normalized to the
total densitometric value for the protein on that immunoblot to
obtain the relative levels of each co-immunoprecipitated protein.
These relative levels of HSPs or FLAG-CHIP were then expressed
as a function of the relative level of co-immunoprecipitated
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ChAT; data were graphed as mean ± SEM from n independent
replicate co-IP experiments. Statistical analysis was performed by
either Student’s t-test, one-way ANOVA with either Tukey’s or
Dunnett’s post-hoc test, or by two-way ANOVA with Bonferroni’s
post-hoc test using GraphPad Prism software.
RESULTS
Identification of the Heat Shock Proteins
HSP70 and HSP90 as Putative ChAT
Protein-Interactors
We showed previously that mutations of the N-terminal
proline-rich motif of ChAT, including P17A/P19A and CMS-
related V18M, enhances ChAT ubiquitination and proteasomal
degradation (Morey et al., 2016). To address the underlying
mechanisms of ChAT ubiquitination and to identify putative
protein-interactors that may differentially regulate mutant ChAT
protein stability, we utilized the BioID proteomics approach
(Roux et al., 2012) to screen for direct and proximal ChAT-
interacting proteins (Figure 1). We chose to compare wild-
type ChAT and P17A/P19A-ChAT for our BioID experiments
as we showed previously that this mutation has the greatest
impact on ChAT ubiquitination and degradation following
modification of the proline-rich motif (Morey et al., 2016).
Thus, HEK293 cells expressing either wild-type or P17A/P19A-
ChAT fused to the 35 kDa HA-tagged promiscuous biotin
ligase BirA-R118G-HA (BirA∗) were treated with either vehicle
(control) or 50µM biotin for 24 h to allow proximity-dependent
biotinylation of ChAT-interacting proteins. Anti-ChAT and anti-
HA immunoblots revealed expression of ChAT-BirA∗ fusion
proteins with apparent molecular mass of∼100 kDa compared to
untagged ChAT proteins at∼70 kDa (Figure 1A, top two panels).
The steady-state levels of P17A/P19A-ChAT-BirA∗ protein was
less than that of wild-type-ChAT-BirA∗ in agreement with our
previous results demonstrating enhanced ubiquitination and
degradation of mutant P17A/P19A-ChAT (Morey et al., 2016).
Furthermore, the BioID-dependent biotinylation of cellular
proteins was analyzed by blotting of samples obtained from
streptavidin pull-downs (PDs) with HRP-conjugated streptavidin
(Strep-HRP). As anticipated, we detected biotinylation of
multiple cellular proteins in samples from biotin-treatedHEK293
cells that expressed ChAT-BirA∗ fusion proteins, but not in
control cells grown in the absence of biotin or in cells expressing
untagged ChAT (Figure 1A). Importantly, the abundance of
several of these biotinylated proteins was different in cells
expressing P17A/P19A-ChAT-BirA∗ compared to wild-type-
ChAT-BirA∗; a protein with apparent molecular mass of ∼70
kDa protein was notably enriched in cells expressing P17A/P19A-
ChAT-BirA∗.
Our initial BioID experiments suggest that multiple proteins
interact with and may differentially regulate mutant P17A/P19A-
ChAT compared to wild-type ChAT. Our primary goal for
using BioID was to identify putative ChAT protein-interactors
that may be responsible for the enhanced ubiquitination and
degradation of mutant ChAT that we observed previously,
and thus identification of proteins enriched in cells expressing
P17A/P19A-ChAT-BirA∗ were of prime interest. Therefore, we
completed a large-scale BioID experiment in HEK293 cells
expressing either wild-type-ChAT-BirA∗ or P17A/P19A-ChAT-
BirA∗ and, following streptavidin PDs, biotinylated proteins
were visualized on a silver stained SDS-PAGE gel (Figure 1B).
Two proteins of interest that were enriched in cells expressing
P17A/P19A-ChAT-BirA∗ with apparent molecular masses of
∼70 kDa and ∼90 kDa were excised from the gel, along with
an intense band at ∼100 kDa correlating with the estimated
molecular mass of the putative P17A/P19A-ChAT-BirA∗ fusion
protein. In-gel protein samples were digested with trypsin and
identified by either matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF-MS) and/or
liquid chromatography-electrospray ionization-tandem mass
spectrometry (LC-ESI-MS/MS). Initial identification by MALDI-
TOF-MS revealed the∼70 kDa protein as the heat shock protein
HSP70 and, as anticipated, the∼100 kDa protein as ChAT-BirA∗
(Figure 1B). Sequence coverage obtained by MALDI-TOF-MS
for human HSP70 was 30% (20 peptides; Supplementary Figure
S1), while coverage for human 69-kDa ChAT and bacterial BirA
were 31% (20 peptides) and 42% (16 peptides), respectively
(Supplementary Figure S2). The ∼100 kDa protein analyzed
from cells expressing P17A/P19A-ChAT-BirA∗ was identified
from the NCBI protein database as ChAT-BirA∗. Our data did
not contain peptides with masses that matched tryptic peptides
that would cover the mutated residues in the P17A/P19A-
ChAT sequence. Identification of the ∼90 kDa protein could
not be achieved by MALDI-TOF-MS due to low sample yield,
though subsequently by using the more sensitive LC-ESI-MS/MS
approach we identified this protein as HSP90 with a 16%
sequence coverage (10 peptides; Supplementary Figure S3). Also
using LC-ESI-MS/MS, we obtained a greater sequence coverage
for HSP70 of 34% (25 peptides; Supplementary Figure S4).
Notably, tryptic peptides with masses indicating the addition
of biotin were detected for both HSP70 and ChAT-BirA∗ by
MALDI-TOF-MS; these peptides contained lysine residues that
could be biotinylated by BirA∗.
To verify the proteins identified by MALDI and LC-
ESI-MS/MS following BioID, we performed anti-HSP70 and
anti-HSP90 immunoblotting on biotinylated protein samples
obtained by streptavidin PDs from biotin-treated HEK293 cells
expressing either wild-type-ChAT-BirA∗ or P17A/P19A-ChAT-
BirA∗ (Figure 1C). Importantly, as anticipated we observed PD
of endogenous HSP70 and HSP90 from biotin-treated cells
expressing P17A/P19A-ChAT-BirA∗; streptavidin PD of these
HSPs were not consistently observed from cells expressing
wild-type-ChAT-BirA∗ (2 of 4 trials). As controls, neither
HSP70 nor HSP90 were visualized in immunoblots following
streptavidin PDs from cells that expressed untagged ChAT.
In addition, anti-ChAT and anti-HA immunoblots revealed
recovery of ChAT-BirA∗, but not untagged ChAT, in streptavidin
PD samples, suggesting that ChAT-BirA∗ can undergo self-
biotinylation. This has been reported in other BioID studies
for BirA∗-tagged proteins (Roux et al., 2012) and confirms our
MALDI-TOF-MS analysis of biotinylated P17A/P19A-ChAT-
BirA∗ (Supplementary Figure S2). Together, our BioID results
have identified the molecular chaperones HSP70 and HSP90
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FIGURE 1 | Identification of the heat shock proteins HSP70 and HSP90 as putative ChAT protein-interactors by proximity-dependent biotin identification (BioID).
(A) Optimization of BioID in HEK293 cells expressing wild-type or P17A/P19A-ChAT fused to the HA-tagged promiscuous biotin ligase BirA-R118G (BirA*). Control
cells were transfected with empty vector or plasmids encoding either untagged ChAT or BirA*. Cells were treated for 24 h with either 50µM biotin to facilitate
proximity-dependent biotinylation of ChAT-interacting cellular proteins or with vehicle-control (water). Biotinylated proteins were isolated from cell lysates by
streptavidin pull-downs (PD: Strep) and immunoblotted as indicated (n = 2). (B) Identification of HSP70 and HSP90 as ChAT proximally-interacting proteins.
Streptavidin PD samples prepared from biotin-treated HEK293 cells expressing wild-type-ChAT-BirA* or P17A/P19A-ChAT-BirA* fusion proteins were resolved and
visualized on a silver-stained SDS-PAGE gels. Two proteins (∼70 and ∼90 kDa) that were enriched in samples expressing P17A/P19A-ChAT-BirA* were identified by
MALDI-TOF-MS or LC-ESI-MS/MS as HSP70 and HSP90, respectively. Control cells were transfected to express untagged wild-type ChAT (n = 1). (C) Confirmation
of endogenous HSP70 and HSP90 as putative ChAT-interacting proteins by immunoblotting of streptavidin PD samples prepared from biotin-treated HEK293 cells
expressing HA-tagged wild-type-ChAT-BirA* or P17A/P19A-ChAT-BirA*. Control cells were transfected with empty vector or vector encoding untagged ChAT (n = 4).
as putative ChAT protein-interactors that are enriched in cells
expressing P17A/P19A-ChAT-BirA∗.
Co-IP of ChAT with HSPs Is Altered by
Mutation of N-terminal Proline-Rich Motif
of ChAT
HSPs, such as HSP70 and HSP90, are well-characterized
molecular chaperones capable of performing protein triage
decisions by either promoting the folding and stabilization of
cellular proteins or by targeting terminally misfolded proteins
for degradation (McClellan and Frydman, 2001; Richter et al.,
2010). As such, these HSPs may represent molecular chaperones
involved in the stabilization of ChAT and/or may promote
degradation of mutant or misfolded ChAT. Therefore, to
verify these putative BioID interactions between ChAT and
endogenous HSP70 and HSP90, we performed co-IP assays
from HEK293 cells expressing either untagged wild-type or
P17A/P19A-ChAT (Figure 2A). Interestingly, both HSP70 and
HSP90 were recovered in anti-ChAT co-IP samples from cells
expressing either wild-type or P17A/P19A-ChAT. We also found
that endogenous HSC70, a constitutively-expressed HSP that has
analogous chaperone function and shares similar client proteins
to that of HSP70 (Liu et al., 2012) co-IPs with ChAT (Figure 2A).
Importantly, by comparing the levels of ChAT protein to HSPs
in anti-ChAT co-IP samples, we find enhanced association
of P17A/P19A-ChAT with endogenous HSP70 (p ≤ 0.001;
Figure 2B), HSP90 (p≤ 0.001; Figure 2C) andHSC70 (p≤ 0.001;
Figure 2D) relative to wild-type ChAT.
Our initial BioID and co-IP experiments were performed
in HEK293 cells as these cells are easily transfected to
express heterologous proteins. As our previous studies on
ChAT ubiquitination and degradation were carried out with
mouse cholinergic SN56 neural cells (Morey et al., 2016), we
confirmed our novel results by performing anti-ChAT co-IPs
from SN56 cells expressing either wild-type or P17A/P19A-
ChAT. Furthermore, to assess whether enhanced association
of ChAT with HSC/HSP70 and HSP90 would also be seen in
selected CMS-related ChAT mutant proteins, we also evaluated
anti-ChAT co-IPs from SN56 cells expressing either V18M- or
A513T-ChAT. We chose to investigate these two catalytically-
deficient CMS-related mutations as we had shown enhanced
ubiquitination and degradation of these ChAT mutant proteins
previously (Morey et al., 2016). Importantly, we detected both
endogenous HSC70 and HSP90 in anti-ChAT co-IP samples
from SN56 cells expressing either wild-type or mutant ChAT
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FIGURE 2 | Co-immunoprecipitation (co-IP) of ChAT with heat shock proteins HSC70, HSP70, and HSP90 is altered by mutation of N-terminal proline-rich motif in
ChAT. (A) Immunoblots showing co-IP of ChAT with endogenous HSC70, HSP70 and HSP90 from HEK293 cells expressing either wild-type or P17A/P19A-ChAT.
Control cells were transfected with empty vector. Using HEK293 cells, co-IP of P17A/P19A-ChAT with HSP70 (B), HSP90 (C) and HSC70 (D), respectively, is greater
than that of wild-type ChAT (***p ≤ 0.001, Student’s t-test, mean ± SEM, n = 4). (E) Co-IP of ChAT with endogenous HSC70 and HSP90 from mouse cholinergic
SN56 cells expressing either wild-type or P17A/P19A-ChAT or CMS-related mutant proteins V18M- or A513T-ChAT. Control cells were transfected with empty vector.
(F) Using SN56 cells, Co-IP of P17A/P19A-ChAT (***p ≤ 0.001) and V18M-ChAT (*p ≤ 0.05), but not A531T-ChAT, with HSC70 is greater than that of wild-type ChAT
(mean ± SEM, n = 5). (G)While there was a trend toward increased HSP90 interaction with P17A/P19A-ChAT (p = 0.09), no significant differences were observed for
HSP90 interaction with mutant ChAT compared to wild-type ChAT in SN56 cells (mean ± SEM, n = 5). Statistical analysis for (F) and (G) was performed by one-way
ANOVA with Dunnett’s post-hoc test. (H) Detection of in situ interactions of wild-type ChAT with endogenous HSC70 and HSP90 by proximity ligation assay (PLA) in
SN56 cells. Formalin-fixed cells were first co-labeled with goat anti-ChAT together with either mouse anti-HSC70 or mouse anti-HSP90 primary antibodies, then
incubated with oligonucleotide-linked secondary antibodies. Following DNA ligation and DNA amplification using the Duolink in Situ Orange Kit (Sigma), in situ
ChAT-HSP interactions were imaged by confocal microscopy. Positive in situ ChAT-HSP interactions where visualized as fluorescent red dots while nuclei were stained
with DAPI (blue). Control cells were either transfected with empty vector or had primary antibodies omitted from the assay (No 1◦ antibodies). Images are
representative of 3 independent experiments; scale bars are 10µm.
proteins (Figure 2E). Unlike HEK293 cells, we did not observe
constitutive expression of HSP70 in SN56 cells. By comparing
the levels of ChAT proteins to endogenous HSC70 in anti-ChAT
co-IP samples, we find enhanced association of P17A/P19A-
(p ≤ 0.001) and V18M-ChAT (p ≤ 0.05), but not A513T-
ChAT, with HSC70 compared to wild-type ChAT (Figure 2F).
Interestingly, there were no significant differences in association
of mutant ChAT with HSP90 in SN56 cells, but there was a trend
toward enhanced HSP90 association with P17A/P17A-ChAT (p
= 0.09; Figure 2G).
To confirm whether HSC70 and HSP90 interact with ChAT
in situ, we performed a proximity ligation assay (PLA) in SN56
cells expressing wild-type ChAT. As predicted, we observed
interaction of wild-type ChAT with endogenous HSC70 and
HSP90 in cells (Figure 2H). Confocal images show that the
ChAT-HSP PLA complexes are predominantly cytoplasmic in
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agreement with the reported subcellular distribution of 69-kDa
ChAT (Resendes et al., 1999). As controls, PLA complexes were
not observed in cells that were transfected with empty vector and
incubated with primary antibodies, or when primary antibodies
recognizing ChAT, HSC70 or HSP90 were omitted from the
assay.
Inhibition of HSC/HSP70 Interaction with
Client Proteins Promotes Accumulation of
High Molecular Mass Triton-Insoluble
ChAT Aggregates
Functionally, HSPs aid in the stabilization of cellular proteins by
interacting with exposed peptide sequences rich in hydrophobic
amino acids, thereby preventing unintended protein aggregation
and promoting protein folding and solubility (McClellan and
Frydman, 2001; Xu et al., 2005; Richter et al., 2010). Therefore,
to test whether HSC/HSP70 may participate in the folding of
ChAT protein, we treated ChAT-expressing SN56 cells with
the HSC/HSP70 inhibitor 2-phenylethynesulfonamide (PES)
(Figure 3), a small-molecule that interferes with HSC/HSP70-
client interactions leading to accumulation and insolubilization
of misfolded and aggregation-prone proteins (Leu et al.,
2009, 2011). Cells were treated with 20µM PES for 24 h,
then Triton-soluble and insoluble ChAT levels were assessed
by immunoblotting to determine levels of misfolded and/or
aggregated ChAT protein (Figure 3A). Importantly, PES
treatment of cells did not alter the levels of Triton-soluble
wild-type or mutant ChAT proteins (Figure 3B), but levels
of Triton-insoluble wild-type (p ≤ 0.01), P17A/P19A- (p
≤ 0.001), V18M- (p ≤ 0.01), and A513T-ChAT proteins
(p ≤ 0.001) were significantly increased compared to levels
found in DMSO-treated control cells (Figure 3C). Moreover,
immunoblots of Triton-insoluble samples from PES-treated
cells revealed accumulation of anti-ChAT immunopositive
high molecular mass proteins and the presence of insoluble
ChAT that did not enter the stacking gels of the SDS-PAGE gels
(Figure 3A, top panel, anti-ChAT immunoblot, long-exposure).
The accumulation of high molecular mass Triton-insoluble
ChAT proteins is greater for mutant ChAT than for wild-type
ChAT, with levels of Triton-insoluble P17A/P19A-ChAT being
the greatest. Interestingly, high molecular mass Triton-insoluble
P17A/P19A-ChAT was also observed in DMSO-treated cells,
though at a lower abundance than in PES-treated cells.
To assess whether the high molecular mass Triton-insoluble
ChAT proteins observed following PES treatment may consist
of detergent-resistant ChAT aggregates, we performed semi-
denaturing detergent agarose gel electrophoresis (SDD-AGE)
(Halfmann and Lindquist, 2008) on Triton-insoluble protein
samples from Figure 3A. Using anti-ChAT immunoblotting, we
observed accumulation of high molecular mass SDS-resistant
ChAT protein aggregates from lysates of PES-treated cells, but
generally not from DMSO-treated control cells (Figure 3D). The
abundance of these insoluble SDS-resistant ChAT aggregates
is greater for mutant ChAT compared to wild-type ChAT,
with P17A/P19A-ChAT being the greatest. Moreover, insoluble
SDS-resistant aggregates of P17A/P19A-ChAT were found in
FIGURE 3 | Inhibition of HSC/HSP70 interaction with client proteins promotes
accumulation of high molecular mass Triton-insoluble ChAT aggregates.
(A) Immunoblots from SN56 cells expressing either wild-type or mutant ChAT
that were treated for 24 h with either 20µM PES, a HSC/HSP70 inhibitor, or
DMSO-vehicle. Cells were lysed in 0.1% Triton X-100 and fractionated into
(Continued)
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FIGURE 3 | soluble and insoluble proteins. Triton X-100 insoluble proteins
were solubilized prior to SDS-PAGE by denaturing in 2x Laemmli sample buffer
with 5% 2-mercaptoethanol. PES treatment resulted in production of high
molecular mass Triton-insoluble ChAT proteins that accumulated in the loading
pockets of the SDS-PAGE gels (top panel, anti-ChAT long-exposure). The
abundance of insoluble ChAT in the loading pockets appears to be greater for
mutant ChAT compared to wild-type ChAT, with levels of Triton-insoluble
P17A/P19A-ChAT appearing the greatest. (B) Treatment with 20µM PES had
no effect on the total levels of Triton-soluble ChAT protein. (C) PES treatment
significantly increased the levels of Triton-insoluble wild-type (**p ≤ 0.01),
P17A/P19A- (***p ≤ 0.001), V18M- (**p ≤ 0.01) and A513T-ChAT (***p ≤
0.001) proteins compared to vehicle-control (two-way ANOVA with
Bonferroni’s post-hoc test, mean ± SEM, n = 6). (D) Triton-insoluble protein
samples from (A) were analyzed by semi-denaturing detergent agarose gel
electrophoresis (SDD-AGE) revealing the presence of insoluble SDS-resistant
ChAT aggregates in PES-treated cells. The abundance of these SDS-resistant
ChAT aggregates is greater for mutant ChAT compared to wild-type ChAT,
with P17A/P19A-ChAT being the greatest (n = 6).
DMSO-treated cells, suggesting that this mutation may promote
ChAT insolubility and aggregation under basal conditions. Taken
together, these results suggest that folding and solubility of ChAT
protein is promoted by interaction of ChAT with HSC/HSP70,
and that the catalytically-deficient ChAT mutant proteins tested
appear more sensitive to PES-induced insolubilization.
Inhibition of HSC/HSP70 ATPase Activity
Reduces ChAT Steady-State Protein Levels
In addition to client protein interaction, the protein-chaperoning
function of HSC/HSP70 requires activity of its N-terminal
ATPase domain, and inhibition of this domain by the small-
molecule VER-155008 promotes the degradation of HSC/HSP70
clients (Massey et al., 2010; Schlecht et al., 2013). Thus, to
determine if HSC/HSP70 activity is required for ChAT protein
stability, SN56 cells expressing either wild-type (Figure 4A),
P17A/P19A- (Figure 4B), V18M- (Figure 4C) or A513T-ChAT
(Figure 4D) were treated with varying concentrations (5–
50µM) of VER-155008 for 24 h. When analyzed by anti-ChAT
immunoblotting, we observed dose-related reductions in the
steady-state protein levels for both wild-type and mutant ChAT
in VER-155008 treated cells. Interestingly, mutant ChAT appears
more sensitive than wild-type ChAT to HSC/HSP70 inhibition.
A significant decrease in wild-type ChAT steady-state protein
level was observed when cells were treated with at least 20µM
VER-155008 (p ≤ 0.05; Figure 4E), while lower concentrations
of VER-155008 were sufficient to significantly reduce protein
levels of P17A/P19A- (5µM; p ≤ 0.001; Figure 4F), V18M-
(5µM; p ≤ 0.001; Figure 4G) or A513T-ChAT (10µM; p ≤
0.001; Figure 4H) compared to DMSO-treated control cells.
Furthermore, treatment of ChAT-expressing cells with 50µM
VER-155008 reduced ChAT steady-state protein levels compared
to DMSO-treated control cells as follows: wild-type ChAT (38.6
± 4.97%), P17A/P19A-ChAT (61.0± 4.17%), V18M-ChAT (75.7
± 2.82%) and A513T-ChAT (53.6 ± 2.69%). To test whether the
loss of ChAT protein following inhibition of HSC/HSP70 was
due to proteasomal degradation of ChAT, we co-treated ChAT-
expressing SN56 cells with VER-155008 and the proteasome
inhibitor MG132. We observed that treatment of cells expressing
either wild-type and mutant ChAT with 40µM VER-155008
reduced ChAT steady-state protein levels, and that co-treatment
of cells with 5µM MG132 attenuated this effect (Figure 4I).
Furthermore, co-treatment of ChAT-expressing SN56 cells with
50µM chloroquine to inhibit lysosome function (Seglen et al.,
1979) did not alter the effects of 40µM VER-155008 on
steady-state levels of either wild-type or mutant ChAT proteins
(Figure 4J).
Inhibition of HSP90 ATPase Activity
Specifically Reduces Steady-State Protein
Levels of Mutant ChAT
Like HSC/HSP70, HSP90 has an N-terminal ATP-binding
domain with ATPase activity that is required for HSP90
chaperoning function, and pharmacological inhibition
of this domain by the small molecule 17-allylamino-17-
demethoxygeldanamycin (17-AAG) promotes proteasomal
degradation of HSP90 clients (Krishnamoorthy et al., 2013). To
determine if HSP90 activity promotes ChAT stabilization, we
treated ChAT-expressing SN56 cells with 0.5–2µM 17-AAG for
24 h (Figure 5). Analysis by anti-ChAT immunoblotting showed
that treatment of cells with concentrations of 17-AAG up to
2µM had no effect on the steady-state levels of wild-type ChAT
protein (Figures 5A,E), but did significantly reduce the steady-
state levels of mutant P17A/P19A- (p ≤ 0.001; Figures 5B,F),
V18M- (p ≤ 0.001; Figures 5C,G) and A513T-ChAT proteins
(p ≤ 0.001; Figures 5D,H) compared to DMSO-treated control
cells. To test if the effects of 17-AAG on ChAT protein levels were
proteasome-dependent, we co-treated SN56 cells expressing
either wild-type or mutant ChAT with 17-AAG and MG132.
Treatment of cells with 1µM 17-AAG alone reduced steady-
state protein levels of only mutant ChAT, while co-treatment
with 5µM MG132 attenuated that effect (Figure 5I). Again,
lysosomal inhibition by treatment of ChAT-expressing SN56
cells with 50µM chloroquine did not prevent the effects of 1µM
17-AAG co-treatment on steady-state levels of either wild-type
or mutant ChAT protein (Figure 5J). Overall, these data suggest
that while the ATPase activity of HSC/HSP70 is necessary for
both wild-type and mutant ChAT protein stability, the ATPase
activity of HSP90 is critical for stabilization of mutant ChAT, but
not wild-type ChAT protein.
Inhibition of HSC/HSP70 and HSP90
Activity Enhances ChAT Ubiquitination and
Reduces ChAT Enzymatic Activity
In addition to protein folding, HSPs perform essential protein
quality control functions by triaging stress-damaged or
terminally misfolded proteins for degradation through the
ubiquitin-proteasome system (McClellan and Frydman, 2001;
Richter et al., 2010). Therefore, to determine if inhibition of
either HSC/HSP70 or HSP90 promotes proteasomal degradation
of ChAT through enhanced ChAT ubiquitination, we treated
ChAT-expressing SN56 cells with either 40µM VER-155008
for 24 h or 1µM 17-AAG for either 8 or 24 h, along with
20µM MG132 during the final 6 h of the incubation to prevent
degradation of ubiquitinated ChAT. Using anti-ChAT IP and
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FIGURE 4 | Inhibition of HSC/HSP70 ATPase activity reduces ChAT steady-state protein levels in a dose-related and proteasome-dependent manner. Immunoblots
from SN56 cells expressing wild-type (A), P17A/P19A- (B), V18M- (C), or A513T-ChAT (D) that were treated for 24 h with 5–50µM VER-155008, an inhibitor of
HSC/HSP70 activity, or with DMSO-vehicle. Steady-state protein levels of wild-type (E), P17A/P19A- (F), V18M- (G), and A513T-ChAT (H) are reduced following
treatment with VER-155008 as compared to vehicle-control (**p ≤ 0.01, ***p ≤ 0.001; one-way ANOVA with Dunnett’s post-hoc test, mean ± SEM, n = 4). Mutant
ChAT appears more sensitive to HSC/HSP70 inhibition where treatment with 50µM VER-155008 reduced ChAT steady-state proteins levels, compared to
vehicle-control, as follows; wild-type ChAT (38.63% ± 4.97), P17A/P19A-ChAT (61.04% ± 4.17), V18M-ChAT (75.71% ± 2.82), and A513T-ChAT (53.60% ± 2.69).
(I) Proteasome inhibition by co-treatment with 5µM MG132 for 18 h attenuates the effects of inhibition of HSC/HSP70 (40µM VER-155008, 24 h) on ChAT
steady-state protein levels in SN56 cells. Control cells were treated with DMSO-vehicle. Proteasome inhibition was validated by immunoblotting for the accumulation
of ubiquitinated cellular proteins (n = 4). (J) Lysosomal inhibition by co-treatment with 50µM chloroquine (CQ) for 18 h did not prevent the effects of VER-155008
treatment (40µM, 24 h) on steady-state levels of ChAT protein in SN56 cells. Lysosomal inhibition was validated by immunoblotting for the accumulation of the
lysosome-associated protein LC3B-II (n = 3).
anti-ubiquitin immunoblotting, we observed that treatment of
cells with VER-155008 resulted in enhanced ubiquitination of
both wild-type and mutant ChAT compared to DMSO-treated
control cells (Figure 6A), with ubiquitination of mutant ChAT,
particularly P17A/P19A-ChAT, being greater than that of
wild-type ChAT. Surprisingly, treatment of cells with 17-AAG
for 24 h had no effect on the ubiquitination of either wild-type
or mutant ChAT proteins compared to DMSO-control, but 8 h
treatment with 17-AAG did enhance ubiquitination of ChAT
with this being greater for mutant ChAT than for wild-type
ChAT, particularly for P17A/P19A-ChAT (Figure 6B).
Canonically, ubiquitination targets proteins for proteasomal
and/or lysosomal degradation, but it can also regulate subcellular
trafficking, receptor endocytosis and enzymatic activity of various
proteins (Sadowski et al., 2012). Therefore, to determine if HSP
inhibition may also affect ChAT enzymatic activity, we treated
SN56 cells expressing heterologous wild-type ChAT with either
40µM VER-155008 or 1µM 17-AAG for 24 h, then analyzed
cellular ChAT activity using a modified radioenzymatic assay
(Fonnum, 1969; Pongrac and Rylett, 1998). Interestingly, we
found that enzymatic activity of wild-type ChAT is significantly
reduced following treatment of SN56 cells for 24 h with either
40µM VER-155008 or 1µM 17-AAG compared to DMSO-
treated control cells (p≤0.01; Figure 6C). The reduction in
cellular ChAT activity appears greater in cells treated with VER-
155008 than with 17-AAG, but this did not achieve statistical
significance (p = 0.074). Importantly, these data show that while
inhibition of HSP90 by 17-AAG treatment had no effect on the
steady-state protein levels of wild-type ChAT (Figures 5A,E),
this treatment did significantly reduce wild-type ChAT enzyme
activity similar to that observed with HSC/HSP70 inhibition.
ChAT Interacts with the HSP-associated E3
Ubiquitin Ligase C-Terminus of
HSC70-Interaction Protein (CHIP)
The E3 ubiquitin ligase CHIP/Stub1 ubiquitinates proteins in
an HSP-dependent manner through direct interaction with
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FIGURE 5 | Inhibition of HSP90 ATPase activity specifically reduces steady-state levels of mutant ChAT protein. Immunoblots from SN56 cells expressing wild-type
(A), P17A/P19A- (B), V18M- (C), or A513T-ChAT (D) that were treated for 24 h with 0.5–2µM with 17-AAG, an inhibitor of HSP90 activity, or with DMSO-vehicle.
(E) Treatment of cells with 17-AAG at concentrations up to 2µM has no effect on the steady-state levels of wild-type ChAT protein. Conversely, steady-state protein
levels of P17A/P19A- (F), V18M- (G), and A513T-ChAT (H) are reduced following treatment of cells with 17-AAG compared to vehicle-control (***p ≤ 0.001; one-way
ANOVA with Dunnett’s post-hoc test, mean ± SEM, n = 4). (I) Proteasome inhibition by co-treatment with 5µM MG132 for 18 h attenuates the effects of inhibition of
HSP90 (1µM 17-AAG, 24 h) on ChAT steady-state protein levels in ChAT-expressing SN56 cells. Control cells were treated with DMSO-vehicle. Proteasome inhibition
was validated by immunoblotting for the accumulation of ubiquitinated cellular proteins (n = 4). (J) Lysosomal inhibition by co-treatment with 50µM chloroquine (CQ)
for 18 h did not prevent the effects of 17-AAG treatment (1µM, 24 h) on steady-state ChAT protein levels in SN56 cells. Lysosomal inhibition was validated by
immunoblotting for the accumulation of the lysosome-associated protein LC3B-II (n = 3).
either HSC/HSP70 or HSP90 and their bound client proteins
(Ballinger et al., 1999; Connell et al., 2001; Zhang et al., 2015).
To determine if ChAT interacts with CHIP, we performed
ChAT co-IPs from SN56 cells co-expressing either wild-type or
mutant ChAT proteins with FLAG-tagged CHIP (Figure 7A).
FLAG-CHIP was detected in anti-ChAT co-IP samples for both
wild-type and mutant ChAT on anti-FLAG immunoblots. By
comparing the levels of FLAG-CHIP to ChAT protein, we
observed enhanced co-IP of FLAG-CHIP with P17A/P19A-
(p ≤ 0.001), V18M- (p ≤ 0.001), and A513T-ChAT (p ≤
0.05) compared to wild-type ChAT (Figure 7B). Association
of wild-type and mutant ChAT with endogenous CHIP was
confirmed by anti-ChAT co-IP from ChAT-expressing SN56
cells with follow-up anti-CHIP immunoblotting (Figure 7C).
We also performed PLA experiments to visualize and confirm,
by confocal microscopy, the presence of in situ interactions
between wild-type ChAT and endogenous CHIP in SN56 cells
(Figure 7D). We did not observe in situ interactions in control
cells that were either transfected with empty vector or when
primary antibodies toward ChAT or CHIP were omitted from the
assay. To determine if ChAT is a substrate for CHIP-mediated
degradation, we tested whether overexpression of FLAG-CHIP
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FIGURE 6 | Inhibition of HSC/HSP70 and HSP90 activity enhances ChAT ubiquitination and reduces cellular ChAT enzymatic activity. (A) Immunoblots following
anti-ChAT IP from ChAT-expressing SN56 cells that were co-treated for 24 h with 40µM VER-155008 and for the final 6 h with 20µM MG132 to inhibit degradation of
ubiquitinated ChAT. Control cells were transfected with empty vector and/or treated with DMSO-vehicle. Inhibition of HSC/HSP70 by VER-155008 treatment
enhanced ChAT ubiquitination, where levels of ubiquitinated mutant ChAT, particularly P17A/P19A-ChAT, are greater than that of wild-type ChAT (n = 3).
(B) Immunoblots following anti-ChAT IP from ChAT-expressing SN56 cells that were co-treated for either 8 or 24 h with 1µM 17-AAG and for the final 6 h with 20µM
MG132. Inhibition of HSP90 by treatment with 1µM 17-AAG for 8 h, but not for 24 h, enhanced ChAT ubiquitination where levels of ubiquitinated mutant ChAT,
particularly P17A/P19A-ChAT, are greater than that of wild-type ChAT (n = 3). (C) Cellular activity of wild-type ChAT is reduced following treatment of SN56 cells for
24 h with either 40µM VER-155008 or 1µM 17-AAG compared to vehicle-treated (DMSO) cells (**p ≤ 0.01). Treatment with VER-155008 trended toward a greater
reduction in ChAT activity compared to 17-AAG (p = 0.074; one-way ANOVA with Tukey’s post-hoc test, mean ± SEM, n = 3).
promotes the degradation of ChAT and, conversely, if siRNA-
mediated knock-down of endogenous CHIP prevents ChAT
degradation in SN56 cells. Interestingly, while overexpression of
FLAG-CHIP led to enhanced proteasomal degradation of both
wild-type and mutant ChAT (Supplementary Figure S5), siRNA-
mediated knock-down of endogenous CHIP had no effect on the
steady-state levels of either wild-type or mutant ChAT proteins
as assessed by anti-ChAT immunoblotting (Figure 7E). Thus,
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FIGURE 7 | ChAT interacts with the HSP-associated E3 ubiquitin ligase C-terminus of HSC70-interaction protein (CHIP). (A) Immunoblots showing co-IP of ChAT
with FLAG-CHIP from SN56 cells co-expressing either wild-type or mutant ChAT protein with FLAG-tagged CHIP. Control cells were transfected with either empty
vector or to express either wild-type ChAT or FLAG-CHIP alone. (B) Co-IP of ChAT with FLAG-CHIP is enhanced for P17A/P19A- (***p ≤ 0.001), V18M- (***p ≤
0.001), and A513T-ChAT (*p ≤ 0.05) as compared to wild-type ChAT (one-way ANOVA with Dunnett’s post-hoc test, mean ± SEM, n = 5). (C) Co-IP of wild-type and
mutant ChAT with endogenous CHIP following anti-ChAT co-IP from ChAT-expressing SN56 cells (n = 3). (D) Detection of in situ ChAT interactions with endogenous
CHIP by proximity ligation assay (PLA) in SN56 cells expressing wild-type ChAT. Formalin-fixed cells were first co-labeled with goat anti-ChAT together with rabbit
anti-CHIP primary antibodies, then incubated with oligonucleotide-linked secondary antibodies. Following DNA ligation and DNA amplification using the Duolink In Situ
Orange Kit (Sigma), in situ ChAT-CHIP interactions were imaged by confocal microscopy. Positive in situ ChAT-CHIP interactions were visualized as fluorescent red
dots while nuclei were stained with DAPI (blue). Control cells were either transfected with empty vector or primary antibodies omitted from the assay (No 1◦
antibodies). Images are representative of 4 independent experiments; scale bars are 10µm. (E) siRNA-mediated knock-down of CHIP has no effect on the
steady-state protein levels of either wild-type or mutant ChAT. ChAT-expressing SN56 cells were co-transfected with 25 nM of either anti-CHIP siRNA or
scramble-control siRNA for 72 h. Control cells were mock-transfected (n = 4).
while these results identify CHIP as a novel ChAT protein-
interactor in cells, the function/s for this interaction is not
known.
Inhibition of the Co-Chaperone
Cdc48/p97/Valosin-Containing Protein
(VCP) Prevents Degradation of
Ubiquitinated ChAT
The co-chaperone VCP modulates HSP clients through
interaction with HSC/HSP70 (Pleasure et al., 1993) and HSP90
(Prince et al., 2005). Previously, we showed that VCP interacts
with ChAT in IMR32 neural cells exposed to oligomeric Aβ1−42
(Dobransky et al., 2003). Therefore, to examine if wild-type
and/or mutant ChAT protein stability is regulated by VCP
under basal conditions, we treated ChAT-expressing SN56
cells for 18 h with 5–10µM Eeyarestatin-I (Eer1), a small-
molecule VCP inhibitor (Wang et al., 2008, 2010). By anti-ChAT
immunoblotting, we observed accumulation of high molecular
mass wild-type and mutant ChAT-immunopositive proteins
following cell treatment with 10µM Eer1, but not in control
cells treated with DMSO (Figure 8A). The abundance of high
molecular mass ChAT is greater for mutant ChAT proteins
than wild-type ChAT, with levels of P17A/P19A-ChAT being
the greatest. Additionally, Eer1 treatment led to accumulation
of insoluble high molecular mass ChAT proteins in the loading
pockets of the SDS-PAGE gels.
VCP has been shown previously to promote proteasome-
dependent degradation of ubiquitinated proteins from both the
ER and the cytoplasm (Dai and Li, 2001; Meyer et al., 2012).
Furthermore, VCP inhibition by Eer1 treatment can result in
the accumulation of ubiquitinated VCP substrates by preventing
their degradation (Wang et al., 2008, 2010). Therefore, to
determine if high molecular mass ChAT observed following Eer1
treatment represents ubiquitinated ChAT, and therefore whether
VCP inhibition may prevent degradation of ubiquitinated
ChAT, we completed anti-ChAT IPs from ChAT-expressing
SN56 cells treated with 10µM Eer1 for 18 h. Importantly, to
maintain proteasome function and to allow for degradation
of ubiquitinated ChAT in cells treated with DMSO-control we
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FIGURE 8 | Inhibition of the co-chaperone Cdc48/p97/Valosin-containing
protein (VCP) prevents degradation of ubiquitinated ChAT. (A) Immunoblots
from ChAT-expressing SN56 cells that were treated for 18 h with 5–10µM
Eeyarestatin-I (Eer1), a VCP inhibitor, or with DMSO-vehicle. Inhibition of VCP
with 10µM Eer1 resulted in the accumulation of high molecular mass
(Continued)
FIGURE 8 | ChAT-immunopositive proteins and the presence of insoluble
ChAT in the loading pockets of the SDS-PAGE gels (top panel, anti-ChAT
long-exposure). The accumulation of high molecular mass ChAT appears
greater for mutant ChAT compared to wild-type ChAT, with levels of
P17A/P19A-ChAT being the greatest (n = 3). (B) Inhibition of VCP attenuates
the degradation of ubiquitinated ChAT. Ubiquitinated ChAT was analyzed by
anti-ubiquitin immunoblotting following anti-ChAT IP from ChAT-expressing
SN56 cells that were treated for 18 h with 10µM Eer1. Control cells were
transfected with empty vector and/or treated with DMSO-vehicle. The
abundance of ubiquitinated ChAT following VCP inhibition is greater for mutant
ChAT, particularly P17A/P19A-ChAT, compared to wild-type ChAT (n = 3).
did not co-treat cells with MG132. Following anti-ubiquitin
immunoblotting of anti-ChAT IP samples, we confirmed that
VCP inhibition prevented the degradation of ubiquitinated
ChAT compared to DMSO-treated cells (Figure 8B). The
abundance of ubiquitinated ChAT following VCP inhibition is
greater for mutant ChAT compared to wild-type ChAT, with
levels of ubiquitinated P17A/P19A-ChAT being the greatest.
These results suggest that the co-chaperone VCP has a role in
regulating the degradation of ubiquitinated ChAT, a mechanism
that is shared between both wild-type and mutant ChAT.
DISCUSSION
In the current study, we identified novel mechanisms for the
regulation of ChAT protein stability involvingmultiplemolecular
chaperones. In brief, we show that ChAT interacts with and is
a client for the heat shock proteins HSC/HSP70 and HSP90,
where inhibition of HSC/HSP70 protein interactions results
in accumulation of insoluble ChAT protein, and inhibition
of HSC/HSP70 and HSP90 activity led to reduced cellular
ChAT activity, along with enhanced ChAT ubiquitination
and proteasome-dependent loss of ChAT protein. The
effects of HSP inhibition appear greater for mutant ChAT
(P17A/P19A-, V18M-, and A513T-ChAT) than for wild-
type ChAT. Though we show that ChAT interacts with the
HSP-associated E3 ubiquitin ligase CHIP, siRNA-mediated
knock-down of CHIP had no effect on ChAT protein
levels. Lastly, we show that the ER- and HSP-associated co-
chaperone VCP regulates the degradation of ubiquitinated
ChAT.
Canonically, HSPs such as HSC/HSP70 and HSP90 have
been characterized for their role in the folding and stabilization
of nascent proteins, as well as refolding of aggregation- and
misfolding-prone proteins during proteotoxic stress (Mosser
et al., 1997; McClellan and Frydman, 2001; Richter et al.,
2010). Multiple HSPs can act together to chaperone client
proteins in a cooperative and processive manner, with initial
recognition and folding of proteins completed by an HSP40-
HSC/HSP70 complex, followed by transfer to HSP90 by HSP70-
HSP90 organizing protein (Hop) and subsequent final folding by
HSP90 (Wegele et al., 2004; Alvira et al., 2014). In the present
study, inhibition of HSC/HSP70 led to the destabilization and
degradation of both wild-type andmutant ChAT, while inhibition
of HSP90 reduced only cellular ChAT activity with no effect on
wild-type ChAT steady-state protein levels. Thus, HSP90 acts
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downstream of HSC/HSP70 to interact with semi- or pre-folded
proteins where formation of stable HSP90-client interactions is
promoted by availability of labile solvent-exposed hydrophobic
domains, such as those found in ligand-binding domains and
enzyme active sites (Xu et al., 2005; Pratt et al., 2008). As
such, HSP90 plays an essential role in the structural maturation
and conformational activation of various cellular kinases or
enzymes involved in a wide array of cell signaling pathways,
such as endothelial nitric oxide synthase (eNOS) (Takahashi and
Mendelsohn, 2003) and the receptor tyrosine kinase ErbB2 (Xu
et al., 2001). This contrasts with HSC/HSP70 that interacts with
a diverse and extensive range of nascent non-native proteins
(20% of all nascent proteins) that minimally contain solvent-
exposed regions enriched with 4–7 hydrophobic residues (Fourie
et al., 1994; Rudiger et al., 1997; Thulasiraman et al., 1999).
Thus, we propose that ChAT protein folding, stability and
cellular activity is regulated in a similar processive manner by
HSC/HSP70 and HSP90 respectively. It is important to note that
inhibition of either HSC/HSP70 or HSP90 resulted in the loss
of cellular ChAT activity, suggesting that cooperation of these
HSPs is essential for the formation of natively-folded and active
ChAT enzyme, and thus may be critical to cholinergic neural
function.
The primary goal of our study was to identify cellular factors
that regulate the stability of ChAT protein, particularly
mechanisms that may be responsible for the enhanced
ubiquitination of mutant ChAT proteins that we observed
previously (Morey et al., 2016). While our data suggest a
critical role for HSC/HSP70 and HSP90 in the folding and
stabilization of wild-type and/or mutant ChAT, these HSPs are
also well-known for their ability to triage mutated, misfolded
and aggregated proteins for proteolytic degradation through
coordination with the HSP-associated E3 ubiquitin ligase
CHIP/Stub1 (Ballinger et al., 1999; Connell et al., 2001; Murata
et al., 2001). HSP-mediated protein degradation often requires
the formation of pro-degradative trimeric complexes between
client-bound HSC/HSP70 or HSP90 and the N-terminal
tetracopeptide repeat (TPR) domains of CHIP (Ballinger
et al., 1999; Smith et al., 2013; Zhang et al., 2015). As such,
studies have reported on the regulation of HSC/HSP70 and
HSP90 client proteins through CHIP-mediated ubiquitination,
including hypoxia-inducible factor 1-alpha (HIF-1α) (Luo
et al., 2010) and ErbB2 (Zhou et al., 2003). The E3 ubiquitin
ligase/s responsible for the ubiquitination of wild-type and/or
mutant ChAT are currently unknown, and while we show here
that ChAT interacts with endogenous CHIP in situ, siRNA
knock-down of CHIP failed to prevent the degradation of
ChAT protein. One possible reason for this observation is that
other HSP-associated E3 ubiquitin ligases may regulate ChAT
ubiquitination as previous studies have demonstrated functional
redundancy for CHIP-mediated degradation of HSP clients in
CHIP-/- mouse fibroblasts (Morishima et al., 2008). Importantly,
the E3 ubiquitin ligase Parkin associates with both HSPs and
CHIP to co-regulate the chaperone-mediated degradation of
HSP clients such as neuronal nitric oxide synthase (nNOS)
and various polyglutamine-expanded proteins (Morishima
et al., 2008; Kumar et al., 2012). In addition, other cytosolic
E3 ubiquitin ligases can also regulate the ubiquitination of
nascent and misfolded HSP clients, including E6-associated
protein (E6-AP) and the N-end rule E3 ligase Ubr1 (Mishra
et al., 2009; Summers et al., 2013). Thus, we hypothesize that
alternative HSP-related E3 ubiquitin ligases, such as Parkin, may
regulate ChAT ubiquitination, potentially in cooperation with
CHIP.
Multiple co-chaperones regulate the function of HSPs,
including HSP40, Hop and CHIP. We showed previously that
the co-chaperone Cdc48/p97/VCP can interact with ChAT in
neural cells exposed to Aβ (Dobransky et al., 2003). VCP
is a member of the AAA-ATPase family that has diverse
cellular functions, including the ability to interact with and
modulate HSC/HSP70 and HSP90 clients (Pleasure et al., 1993;
Prince et al., 2005), and interact with ubiquitinated proteins to
regulate their subcellular trafficking and degradation (Dai and
Li, 2001; Meyer et al., 2012). In the present study, we show
that pharmacological inhibition of VCP led to the accumulation
of ubiquitinated ChAT and prevented its degradation. Related
to its proteolytic functions, studies have demonstrated a role
for VCP in the handling and degradation of protein aggregates
(Ju et al., 2008), as well as in the degradation of ubiquitinated
proteins by the autophagy-lysosomal system (Ju et al., 2009;
Tresse et al., 2010). While the autophagy-lysosomal system is one
possible mechanism involved in the VCP-mediated degradation
of ubiquitinated ChAT, we have shown both previously and
within this study that ChAT protein degradation is largely
unaffected by lysosomal inhibition and, conversely, is regulated
chiefly by the proteasome (Morey et al., 2016). Interestingly,
VCP is best known for its role in promoting the proteasome-
dependent degradation of ER-associated protein degradation
(ERAD) substrates (Dai and Li, 2001; Meyer et al., 2012),
where VCP is critical for ER-to-cytoplasm transfer of proteins
ubiquitinated in the ER, thereby directly mediating degradation
of ERAD substrates by the cytosolic 26S-proteasome (Ye et al.,
2005). Furthermore, VCP influences ubiquitination of ERAD
substrates by interacting with the ER-associated E3 ubiquitin
ligases gp78/AMFR and Hrd1/SYVN1 (Zhong et al., 2004; Ye
et al., 2005; Ballar et al., 2011) that act downstream of 78-
kDa glucose-regulated protein (GRP-78), an ER-associated HSP
known to promote protein folding and stability of nascent
proteins in a manner similar to that of HSC/HSP70 (Hirsch
et al., 2009). Therefore, an alternative possibility by which
VCP regulates the degradation of ubiquitinated ChAT may
involve ERAD-associated mechanisms in addition to those
related to cytosolic HSPs, and thus we hypothesize that
ChAT may be regulated by various cytosolic and/or ER-
associated chaperones that act cooperatively to promote ChAT
protein function. Importantly, while our data suggest that the
proteasomal degradation of ubiquitinated ChAT is promoted
by VCP, it is unclear whether this pro-degradative function of
VCP is primarily HSP- or ER-associated; this requires further
investigation.
We showed previously that ubiquitination of the catalytically-
deficient and CMS-related mutant ChAT proteins V18M-
and A513T-ChAT, as well as P17A/P19A-ChAT, is enhanced,
resulting in increased proteasomal degradation and loss of
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mutant ChAT protein (Morey et al., 2016). All three of these
mutations are positioned distal to the ChAT active site (Kim et al.,
2006; Shen et al., 2011), andwhile themechanisms responsible for
the loss ofmutant ChAT protein inmammalian cells are not clear,
one possibility is that these mutations may produce local changes
to the ChAT protein secondary structure that are responsible for
both the impairment of ChAT catalytic activity and that target
these ChAT mutants for chaperone-mediated degradation. In
the present study, we observed enhanced interaction of mutant
ChAT proteins with HSC/HSP70 and HSP90 and increased
sensitivity ofmutant P17A/P19A-ChAT andCMS-related V18M-
and A513T-ChAT to HSP inhibition where, importantly, HSP90
inhibition resulted in the proteasomal loss of mutant but not
wild-type ChAT. In general, HSPs aid in the stabilization of
their clients through a process of kinetic partitioning, whereby
they interact with exposed hydrophobic domains within cellular
proteins that is thought to prevent client protein misfolding
and aggregation (Rudiger et al., 1997; Xu et al., 2005; Kim
et al., 2013). In support of this, we found that inhibition
of HSC/HSP70-client interactions by PES treatment resulted
in loss of ChAT protein solubility and the generation of
detergent-resistant ChAT aggregates; the abundance of these
PES-induced insoluble ChAT proteins was greatest for mutant
ChAT. Interestingly, insoluble aggregates of mutant P17A/P19A-
ChAT protein was observed in cells with functional HSPs,
suggesting that the folding of this mutant ChAT protein may be
compromised under basal conditions resulting in the production
of catalytically-deficient ChAT that may be susceptible to
misfolding and inactivation. While our results suggest that
HSC/HSP70 and HSP90 are critical for the stabilization of
mutant ChAT, these HSPs are also known to promote the
degradation of misfolded proteins through the ubiquitin-
proteasome system (McClellan and Frydman, 2001; Kim et al.,
2013; Zhang et al., 2015). Importantly, we observed enhanced
ubiquitination of ChAT following HSP inhibition, suggesting
that impairment of HSP-mediated folding of ChAT protein may
promote the ubiquitination and degradation of misfolded ChAT.
Therefore, taken together, our data suggest that mutations, such
as CMS-related V18M and A513T, may compromise ChAT
protein folding and lead to enhanced chaperone-mediated ChAT
degradation and/or enhanced dependence of mutant ChAT
proteins on HSPs to maintain mutant ChAT stability and
function.
Our HSP observations related to mutant ChAT are significant
as protein misfolding and enhanced functional dependence
on molecular chaperones is frequently observed for mutated
and disease-relevant proteins (Valastyan and Lindquist, 2014;
Hartl, 2017). Thus, these observations may represent a general
HSP-related mechanism for the regulation of ChAT protein
stability that may apply to not only various CMS-related
ChAT mutants beyond those studied presently, but also to
the maintenance of ChAT function during cellular stress and
disease. Alterations in the catalytic activity of ChAT have been
observed in several protein misfolding neurological diseases,
including AD and Huntington’s disease (Lange et al., 1992;
Pakaski and Kalman, 2008), both of which are known to
exhibit dysfunction of HSPs and other molecular chaperones,
accumulation of aggregate-prone proteins, and build-up of
proteotoxic and oxidative stress (Mati et al., 2014; Lackie
et al., 2017). Protein oxidation with subsequent formation of
aberrant stress-induced disulfide bonds during cellular exposure
to oxidative stress can result in misfolding of cellular proteins
with severe functional consequences (Cumming et al., 2004).
Interestingly, ChAT has a higher-than-average cysteine content
(3.2% vs. 1.6% for intracellular proteins) (Fahey et al., 1977)
which may sensitize ChAT to oxidative damage. In support,
Nunes-Tavares et al. (2012) demonstrated that cellular ChAT
activity is reduced following exposure of neural cells to
oligomeric Aβ1−42, a molecular hallmark of AD and stimulator of
cellular oxidative stress (Butterfield, 2002; Pakaski and Kalman,
2008). Additionally, our lab has shown that Aβ1−42 treatment
results in stable interaction of ChAT with VCP (Dobransky
et al., 2003) and in the current study we provide evidence that
VCP may regulate and promote degradation of ubiquitinated
ChAT, suggesting that ChAT ubiquitination may be altered
during cellular stress. The E3 ligase Parkin is another example
of a cysteine-rich intracellular protein (7.5%) that has been
shown to misfold, inactivate and aggregate following exposure
to H2O2 (Meng et al., 2011). Therefore, it will be important
to investigate if ChAT protein folding and stability is altered
during cellular stress and disease, and whether HSPs play
a protective role to maintain ChAT function under these
stresses.
HSPs and other molecular co-chaperones are best
characterized for their essential roles in the folding of nascent
and misfolded proteins. In this study, we provide evidence
for the regulation of ChAT protein stability by a network
of cytoplasmic and ER-associated chaperones that includes
HSC/HSP70, HSP90 and VCP. Furthermore, regulation of
ChAT mutants by these chaperones is altered, suggesting
a mechanism that may be relevant to other CMS-related
ChAT mutant proteins or to ChAT during cellular stress and
disease. Taken together, our results support further research
into the roles of HSPs and VCP on ChAT function under
both physiological conditions and during cellular stress and
disease.
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